Major Contributions

Endothelium

• Role of cytochrome P450-derived hyperpolarizing factors (EDHF) in endothelium-dependent vasodilatation in human, and consequences of its pharmacological restoration in cardio-metabolic diseases (PMID: 20083732 22412088 26022136 30885203 31436984)
• Endothelial protective effects and reduction of heart failure by tyrosine phosphatase 1B inhibition (PMID: 22446161 17101854 24760754 27059805 29569957)
  
• Dopamine and endothelial dysfunction in autosomal dominant polycystic kidney disease (PMID: 25029430 30607032)
• Endothelial impact of antiphosphospholipid syndrome and thrombotic thrombocytopenic purpura (PMID: 25047402 27501520 30870459)

Valvulopathy

• Discovery and clinical evaluation of percutaneous aortic valve replacement (PMID:12473543 15226213 22551129 26369474 30028301)

Heart Failure

• Beneficial effects of pharmacological heart rate reduction in heart failure (PMID:14981003 22075752) and acute heart failure (PMID: 33471946)
  
• Aldosterone signaling in heart failure (PMID: 26902493 29061727 29862614  29981797 29862614)
• Treatment of heart failure by localized slow delivery of angiogenic or lymphangiogenic growth factors (PMID:21824923 26933083 30333526 )
• Role of cardiac lymphatics and therapeutic lymphangiogenesis in myocardial infarction and heart failure (PMID: 26933083 30333526 32762908 32404007 32451732)

Patents

• WO2020058201 - UTILISATION D'INHIBITEURS DE L'ACTIVITÉ PHOSPHATASE D'ÉPOXYDE SOLUBLE POUR LE TRAITEMENT DE MALADIES CARDIOMÉTABOLIQUES
• WO2012119980 - PARTICULES CONTENANT UN FACTEUR DE CROISSANCE, ET UTILISATIONS DE CELLES-CI
• WO2018178253 - COMPOSITIONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES DANS LE TRAITEMENT DE LA CALCIFICATION CARDIOVASCULAIRE
• WO2020178441 - INHIBITEURS DE PROTÉINE NGAL